106 related articles for article (PubMed ID: 10860888)
21. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins.
Grundner C; Pancera M; Kang JM; Koch M; Sodroski J; Wyatt R
Virology; 2004 Dec; 330(1):233-48. PubMed ID: 15527849
[TBL] [Abstract][Full Text] [Related]
22. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
23. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
24. Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.
Thiriart C; Francotte M; Cohen J; Collignon C; Delers A; Kummert S; Molitor C; Gilles D; Roelants P; van Wijnendaele F
J Immunol; 1989 Sep; 143(6):1832-6. PubMed ID: 2476484
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
[TBL] [Abstract][Full Text] [Related]
26. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
28. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
[TBL] [Abstract][Full Text] [Related]
29. Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees.
Rovinski B; Dekaban GA; Cao SX; Yao FL; Persson R; Matthews TJ; Klein MH
Virology; 1999 May; 257(2):438-48. PubMed ID: 10329554
[TBL] [Abstract][Full Text] [Related]
30. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.
Paul NL; Marsh M; McKeating JA; Schulz TF; Liljeström P; Garoff H; Weiss RA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):963-70. PubMed ID: 8280479
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus vaccine strains genetically engineered to express HIV-1 or HBV antigens for use as live recombinant vaccines.
Hung PP; Chanda PK; Natuk RJ; Mason BB; Chengalvala M; Bhat BM; Molnar-Kimber KL; Dheer SK; Morin JE; Mizutani S
Nat Immun Cell Growth Regul; 1990; 9(3):160-4. PubMed ID: 2196459
[TBL] [Abstract][Full Text] [Related]
32. Computer predictions of antigenic domains in human immunodeficiency virus-1 envelope glycoprotein: comparison with reported experimental data.
Becker Y
Virus Genes; 1990 Apr; 3(4):323-41. PubMed ID: 1693457
[TBL] [Abstract][Full Text] [Related]
33. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.
Kong L; Sheppard NC; Stewart-Jones GBE; Robson CL; Chen H; Xu X; Krashias G; Bonomelli C; Scanlan CN; Kwong PD; Jeffs SA; Jones IM; Sattentau QJ
J Mol Biol; 2010 Oct; 403(1):131-147. PubMed ID: 20800070
[TBL] [Abstract][Full Text] [Related]
34. Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist.
Kent KA; Robinson J
AIDS; 1996; 10 Suppl A():S107-14. PubMed ID: 8883617
[No Abstract] [Full Text] [Related]
35. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis.
Takefman DM; Sullivan BL; Sha BE; Spear GT
Virology; 1998 Jul; 246(2):370-8. PubMed ID: 9657955
[TBL] [Abstract][Full Text] [Related]
36. Mapping out the intricate relationship of the HIV envelope protein and the membrane environment.
Klug YA; Rotem E; Schwarzer R; Shai Y
Biochim Biophys Acta Biomembr; 2017 Apr; 1859(4):550-560. PubMed ID: 27793589
[TBL] [Abstract][Full Text] [Related]
37. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA.
Giraud A; Ataman-Onal Y; Battail N; Piga N; Brand D; Mandrand B; Verrier B
J Virol Methods; 1999 Apr; 79(1):75-84. PubMed ID: 10328537
[TBL] [Abstract][Full Text] [Related]
38. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.
Johnson JE; Schnell MJ; Buonocore L; Rose JK
J Virol; 1997 Jul; 71(7):5060-8. PubMed ID: 9188571
[TBL] [Abstract][Full Text] [Related]
39. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.
Karlsson GB; Gao F; Robinson J; Hahn B; Sodroski J
J Virol; 1996 Sep; 70(9):6136-42. PubMed ID: 8709238
[TBL] [Abstract][Full Text] [Related]
40. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
Yang X; Wyatt R; Sodroski J
J Virol; 2001 Feb; 75(3):1165-71. PubMed ID: 11152489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
